Home Topics

Topics

3D Printing of Biological Tissues Advanced with Yield Stress Gels

By using a yield stress gel, Penn State engineers can place tiny aggregates of cells exactly where they want to build the complex shapes that will be necessary to replace bone, cartilage, and other tissues.

Traveling through Space and Time: Trajectories of Our Most Powerful Immune Cells

Immune medicines, across cancers, infectious disease, and inflammatory disease, hold our closest promise to lasting curative therapies. In this sponsored webinar, IsoPlexis and various researchers will speak about the shift in space and time towards ‘Smaller’ to target our most powerful single cells, in order to accelerate timelines for finding these cures.

Ori Biotech Raises $30 Million in Financing

Funds will be used to advance innovation in cell and gene therapy manufacturing.

Tumor Cell Microenvironment Altered by Chronic Jet Lag

Researchers report that chronic jet lag alters the microenvironment surrounding tumor cells, making it more favorable for tumor growth, and also hinders the body’s natural immune defenses. Their study highlights the rapidly growing scientific field of the effect of circadian disruption on health and wellbeing.

Neural Network Filters Weak and Strong External Stimuli to Help Brain Make “Yes or No” Decisions

A University of Michigan-led research team has uncovered a neural network that enables Drosophila melanogaster fruit flies to convert external stimuli of varying intensities into a "yes or no" decision about when to act. Using genetic techniques, the researchers were able to show how the Drosophila nervous system can mute or boost different intensities of sensory information to make behavioral decisions.

Protein That Pumps the Brakes on Macrophages in Immune Overreaction

Macrophages are specialized cells involved in the detection, phagocytosis, and destruction of bacteria and other harmful organisms. Using a mouse model, researchers at the University of California San Diego School of Medicine report they have discovered that the protein, GIV, or Girdin, acts as a brake on macrophages.

Multiple Coronaviruses, Same Drug Targets

A comparative viral-human protein-protein interaction and viral protein localization analysis was performed for three coronaviruses—SARS-CoV-2, SARS-CoV-1, and MERS-CoV. The resulting molecular insights, together with drug performance information derived from medical records for about 740,000 SARS-CoV-2 patients, suggested treatment regimens for current, and potential future viral pandemics.

Telomere-Preserving RNA Guided by DNA Repair Enzyme

Research headed by a team at the École Polytechnique Fédérale de Lausanne (EPFL), in Switzerland, generated new insights into how RNA molecules that help to protect the tips of chromosomes are directed to the telomeres. Their experiments showed that when TERRA RNA reaches the tip of chromosomes, proteins regulate its association with telomeres. Among these proteins, RAD51 was shown to play a particularly important role.

Blood Test Potentially Improves Glioma Diagnosis and Monitoring

The TERT gene mutations C228T and C250T are known to promote cancer growth and are present in more than 60% of all gliomas. Now researchers at Massachusetts General Hospital have developed an enhanced form of liquid biopsy that can detect and monitor the genetic mutations in glioma blood samples.

Organoids Can Grow Faster by Compressing Cells

Scientists at MIT and Boston Children’s Hospital say that in the microscopic environment within a single cell, physical crowding increases the chance for interactions in a way that can significantly alter a cell’s health and development. The researchers found that physically squeezing cells, and crowding their contents, can trigger cells to grow and divide faster than they normally would.

Working with ALS Mice: Guidelines for Preclinical Testing and Colony Management

Sponsored content brought to you by Amyotrophic Lateral Sclerosis (ALS) is a devastating and rapidly fatal disease with currently only one available, FDA-approved, modestly effective...

A ‘Patch’-Work Solution to Vaccine Delivery

The contract from BARDA (75A50120C00180) will fund an upcoming Phase I clinical validation study designed to evaluate HD-MAP for pandemic influenza in 420 people, using both unadjuvanted and adjuvanted vaccine formulations. However, Vaxxas is also actively investigating opportunities to apply HD-MAP toward improving the performance of vaccines for other pandemics—including against COVID-19.

The Great Convergence: How Biology and Engineering Unite to Reshape our World

In this webinar—the third in the “Women in Science” series co-hosted by GEN and the Rosalind Franklin Society—renowned neuroscientist Dr. Susan Hockfield, who served as president of MIT from 2004–2012, will share her views of the future that she lays out in her recent book, The Age of Living Machines: How Biology Will Build the Next Technology Revolution.

Biomanufacturing Assumes Central Role in Cell and Gene Therapies

In this GEN Keynote webinar, Dr. Peter Marks, director of the Center for Biologics Evaluation and Research (CBER) at the FDA, will share how CBER is providing oversight to organizations during the critical developmental and manufacturing stages for biological products, as well as throughout the product life cycle.

Days After EUA Request, Lilly Pauses Phase III COVID-19 Antibody Trial

The pause affects the ACTIV-3 trial (NCT04501978), sponsored by the NIH’s National Institute of Allergy and Infectious Diseases. ACTIV-3 is designed to assess the safety and effectiveness of LY-CoV555 compared with Gilead Sciences’ Veklury™ (remdesivir) and placebo in people who have been hospitalized with COVID-19.

NIAID Trial Examines Remdesivir, Antibody Candidates vs. COVID-19

ACTIV-5/BET (NCT04583969) will evaluate Skyrizi® (risankizumab-rzaa), the Boehringer Ingelheim/AbbVie monoclonal antibody now marketed for moderate to severe plaque psoriasis, with remdesivir, compared to a placebo plus remdesivir. The trial will also test Humanigen’s monoclonal antibody candidate lenzilumab with remdesivir, compared to placebo and remdesivir.

MilliporeSigma Launches VirusExpress Lentiviral Production Platform

Company says the new technology helps to overcome lentiviral production challenges and can reduce process development time by approximately 40%.

Wasp Venom Used to Potentially Combat Antibiotic-Resistant Bacteria

Novel antibiotics are urgently needed to treat the ever-increasing number of drug-resistant infections. Now, scientists from the Perelman School of Medicine at the University of Pennsylvania report they engineered bacteria-killing molecules from wasp venom.

Bacterial Toxin Found to Stimulate Tissue Regeneration

A research team has discovered that a bacterial toxin stimulates tissue regeneration in the planarian animal model. Besides harming the host, the toxin may exert beneficial functions by stimulating SPM production to promote the resolution of infectious inflammation.

600 Trillion Synapses and Alzheimers Disease

Sponsored content brought to you by Late-onset Alzheimer’s disease is extremely difficult to model in the laboratory, one reason why no successful therapy for it...

Recently Featured

Scroll Up